Publications

REFEREED JOURNAL PUBLICATIONS

Managing Director

Aquesta Uropathology

Professor of Pathology

The University of Queensland

School of Medicine

Visiting Medical Officer

Greenslopes Private Hospital

 


 

ARTICLES PUBLISHED IN PROFESSIONAL JOURNALS

240. Samaratunga H, DelahuntB, EgevadL. Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/ 10.1016/j.eururo.2021.11.019

239. Roberts MJ, Morton A, Papa N, Franklin A, Raveenthiran S, Yaxley WJ, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Emmett L, Yaxley JW. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022 Mar 17. doi: 10.1007/s00259-022-05756-2. Online ahead of print.

238. Lindh C, Samaratunga H, Delahunt B, Bergström R, Chellappa V, Yaxley J, Lindberg J, Egevad L. Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. Prostate. 2022 ;82:576-583.

237. Bulten W, Kartasalo K, Chen PC, Ström P, Pinckaers H, Nagpal K, Cai Y, Steiner DF, van Boven H, Vink R, Hulsbergen-van de Kaa C, van der Laak J, Amin MB, Evans AJ, van der Kwast T, Allan R, Humphrey PA, Grönberg H, Samaratunga H, Delahunt B, Tsuzuki T, Häkkinen T, Egevad L, Demkin M, Dane S, Tan F, Valkonen M, Corrado GS, Peng L, Mermel CH, Ruusuvuori P, Litjens G, Eklund M; PANDA challenge consortium. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nat Med. 2022 Jan;28(1):154-163. doi: 10.1038/s41591-021-01620-2. Epub 2022 Jan 13.

236. Delahunt B, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Kenwright DN, Matthews J, Murray JD, Oldmeadow C, Samaratunga H, Spry NA, Thunders MC, Hondermarck H, Denham JW.  Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology. 2022;54:49-54

235. Fuchs TL, Maclean F, Turchini J, Vargas AC, Bhattarai S, Agaimy A, Hartmann A, Kao CS, Ellis C, Bonert M, Leroy X, Kunju LP, Schwartz L, Matsika A, Williamson SR, Rao P, Divatia M, Guarch R, Algaba F, Balancin ML, Zhou M, Samaratunga H, da Cunha IW, Brimo F, Ryan A, Clouston D, Aron M, O’Donnell M, Chan E, Hirsch MS, Moch H, Pang CY, Wah C, Yin W, Perry-Keene J, Yilmaz A, Chou A, Clarkson A, van der Westhuizen G, Morrison E, Zwi J, Hes O, Trpkov K, Gill AJ. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Mod Pathol  2021 Dec 23. doi: 10.1038/s41379-021-00998-1. Online ahead of print 

234. Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, Kua B, Samaratunga H, Delahunt B, Egevad L, Wong D, McEwan L, Brown N, Parkinson R, Esler R, Yaxley JW. Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer. J Urol 2022;207(3):573-580

233. Attia A, Morton A, Raveenthiran S, Samaratunga H, Desai D. Lichen sclerosus presenting as an isolated bulbar urethral stricture. Urol Case Rep. 2021 Aug 1;39:101794. doi: 10.1016/j.eucr.2021.101794. eCollection 2021 Nov.

232. Kartasalo K, Bulten W, Delahunt B, Chen PC, Pinckaers H, Olsson H, Ji X, Mulliqi N, Samaratunga H, Tsuzuki T, Lindberg J, Rantalainen M, Wählby C, Litjens G, Ruusuvuori P, Egevad L, Eklund M. Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps. Eur Urol Focus. 2021;7:687-691

231. Samaratunga H, Delahunt B, Yaxley JW, Johannsen S, Egevad L. Intraductal Carcinoma of the Prostate: Extreme Nuclear Size Is Not a Diagnostic Parameter. Am J Surg Pathol. 2021 Nov 1;45:1527-1533

 230. Egevad L, Delahunt B, Samaratunga H, Tsuzuki T, Yamamoto Y, Yaxley J, Ruusuvuori P, Kartasalo K, Eklund M.The emerging role of artificial intelligence in the reporting of prostate pathology. Pathology 2021;53:565-567.

229. Meijer D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Oprea-Lager DE, Coughlin GD, Vis AN.External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.Eur Urol 2021;80:234-242.

228. van der Kwast TH, van Leenders GJ, Berney DM, Delahunt B, Evans AJ, Iczkowski KA, McKenney JK, Ro JY, Samaratunga H, Srigley JR, Tsuzuki T, Varma M, Wheeler TM, Egevad L. ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am J Surg Pathol. 2021 1;45:1118-1126.

227. Iczkowski KA, van Leenders GJLH, Tarima S, Wu R, Van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Ro JY, Samaratunga H, Delahunt B, Srigley J, Varma M, Tsuzuki T, Egevad L. Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Ann Diagn Pathol. 2021 Jun;52:151733. doi: 10.1016/j.ann diagpath.2021.151733. Epub 2021 Mar 22

226. van der Kwast T, Liedberg F, Black PC, Kamat A, van Rhijn BWG, Algaba F, Berman DM, Hartmann A, Lopez-Beltran A, Samaratunga H, Varma M, Cheng L. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. 2021 Mar 23:S2405-4569(21)00096-1. doi: 10.1016/j.euf.2021.03.017. Online ahead of print.

225. Delahunt B, Samaratunga H, Egevad L. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Should Chromophobe Renal Cell Carcinoma Be Graded? Eur Urol. 2021;79:e141-e142. doi: 10.1016/j.eururo.2021.02.003. Epub 2021 Feb 19.

224. Egevad L, Delahunt B, Samaratunga H, Tsuzuki T, Olsson H, Ström P, Lindskog C, Häkkinen T, Kartasalo K, Eklund M, Ruusuvuori P. Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. Virchows Arch 2021;478:1109-1116

223. Akgul M, Williamson SR, Ertoy D, Argani P, Gupta S, Caliò A, Reuter V, Tickoo S, Al-Ahmadie HA, Netto GJ, Hes O, Hirsch MS, Delahunt B, Mehra R, Skala S, Osunkoya AO, Harik L, Rao P, Sangoi AR, Nourieh M, Zynger DL, Smith SC, Nazeer T, Gumuskaya B, Kulac I, Khani F, Tretiakova MS, Vakar-Lopez F, Barkan G, Molinié V, Verkarre V, Rao Q, Kis L, Panizo A, Farzaneh T, Magers MJ, Sanfrancesco J, Perrino C, Gondim D, Araneta R, So JS, Ro JY, Wasco M, Hameed O, Lopez-Beltran A, Samaratunga H, Wobker SE, Melamed J, Cheng L, Idrees MT. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. J Clin Pathol 2021;74:291-299.

222. Egevad L, Samaratunga H, Eble JN. Recent advances in urological pathology. Pathology 2021;53:1-2.

221. Egevad L, Delahunt B, Bostwick DG, Cheng L, Evans AJ, Gianduzzo T, Graefen M, Hugosson J, Kench JG, Leite KRM, Oxley J, Sauter G, Srigley JR, Stattin P, Tsuzuki T, Yaxley J, Samaratunga HProstate cancer grading, time to go back to the future. BJU Int 2021;127:165-168.

220. Samaratunga H, Delahunt B, Yaxley J and Egevad L. Tumour-like lesions of the urinary bladder. Pathology 2021; 53:44-55.

219. Egevad L, Delahunt B, Furusato B, Tsuzuki T, Yaxley J and Samaratunga H. Benign mimicsOf prostate cancer. Pathology 2021 53:26-35.

218. Delahunt B, Eble JN, Samaratunga H, Thunders M, Yaxley JW and Egevad L. Staging of renal cell carcinoma: Current progress and potential advances. Pathology 2021 2021;53:120-128.

217. Franklin A, Delahunt B, Egevad L, Yaxley J, Johannsen S, Gianduzzo T, Ganter J, Pecoraro C,Thunders M, Samaratunga H. Prognostic significance of morphologic patterns of Gleason grade 5prostatic adenocarcinoma diagnosed on needle biopsy. Pathology 2021;53:199-204.

216. Delahunt B, Egevad L, Samaratunga H, Srigley JR, Cheng L, Clouston D, Furusato B, Kench J, Leite KRM, MacLennan GT, Moch H, Pan C-C, Ro J, Tsuzuki T, van der Kwast T, Wheeler T andYaxley JW. Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology 2021;78:342-344.

215. Yaxley WJ, Nouhaud FX, Raveenthiran S, Franklin A, Donato P, Coughlin G, Kua B, Gianduzzo T, Wong D, Parkinson R, Brown N, Samaratunga H, Delahunt B, Egevad L, Roberts M, Yaxley JW.Yaxley WJ, et al. Among authors: samaratunga h.  Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer Prostatic Dis. 2020 In press

214. Bulten W, Balkenhol M, Belinga J-J A, Brilhante A, Çakır A, Egevad L, Eklund M, Farré X,Geronatsiou K, Molinié V,  Guilherme S, Pereira G,  Roy P, Saile G, Salles P, Schaafsma E, TschuiJ, Vos A-M, ISUP Pathology Imagebase Expert Panel including Samaratunga H, van Boven H, Vink R, van der Laak J, Hulsbergen-van der Kaa C, Litjens G. Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Modern Pathology inpress.

213. Samaratunga H, Delahunt B, Srigley JR, Cheng L, Evans AJ, Furusato B, Leite KRM, MacLennan GT, MartignoniG, Moch H, Pan C-C,  Paner G, Ro J, Thunders M, Tsuzuki T, Wheeler T, van der Kwast T, Varma M, Williamson SR and Lars Egevad L. Granular necrosis: A distinctive form of cell death in malignant tumours.  Pathology 2020; 52: 507-514.

212. Egevad L, Swanberg D, Delahunt B, Ström P, Kartasalo K, Olsson H, Berney DM, Bostwick DG, Evans AJ, Humphrey PA, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M, Eklund M. Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Arch 2020 477:777-786.

211. Egevad L, Delahunt B, Tsuzuki T, Furusato B, Samaratunga H. Common benign mimicsof prostate cancer. Diag Histopathol 2020; 26: 305-311.

210. Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, WongD, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts M and Yaxley JW.Histological comparison between predictive value of pre-operative 3T multiparametric MRI versus 68Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International 2021;127:71-79.

209. Juhlin CC, Asa SL, Jatta K, Naserhojati Rodsari H, Shabo I, Haglund F, Delahunt B, Samaratunga H, Egevad L, Höög A, Zedenius J. Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion.  Head Neck Pathol 2020 Jun 9. doi: 10.1007/s12105-020-01187-3. Online ahead of print

208. van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF,Litjens G, McKenney JK, Melamed J, Mottet N, Paner GP, Samaratunga H, Schoots IG, Simko JP,Tsuzuki T, Varma M, Warren AY, Wheeler TM, Williamson SR,, The ISUP Grading Workshop participants, and Kenneth A. Iczkowski KA, MD. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology 2020; 44: e87-e99.

207. Egevad L, Ström P, Kartasalo K, Olsson H, Samaratunga H, Delahunt B, Eklund M. The utility of artificial intelligence in the assessment of prostate pathology. Histopathology 2020; 76:790-792.

206. Delahunt B, Murray JD, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Matthews J, Oldmeadow C, Samaratunga H, Spry NA, Srigley JR, Hondermarck H, Denham JW. Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis:  Ten year data from the TROG 03.04 RADAR Trial. Histopathology 2020; 77: 284-292.

205. Franklin A, Gianduzzo T, Yaxley J, Kua B, Coughlin G, Samaratunga H, Gianduzzo T. Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy. BJU Int 2020; 126:6-11.

204 Ström P, Nordström T, Delahunt B, Samaratunga H, Grönberg H, Egevad L and Eklund M. Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. Journal of Clinical Pathology 2020;73: 630-635.

203. Ström P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Humphrey PA, Iczkowski KA, Kench JG, Kristiansen G, van der Kwast TH, Leite KRM, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, Varma M, Zhou M, Lindberg J, Lindskog C, Ruusuvuori P, Wählby C, Grönberg H, Rantalainen M, Egevad L, Eklund M. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol 2020;21:222-232.

202. Compérat E, Srigley JR, Brimo F, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks JH, Tsuzuki T, van der Kwast T, Varma M, Webster F and Grignon D. Dataset for the reporting of carcinoma of the bladder - cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Virchows Archiv 2020; 476: 521-534.

201. Samaratunga H, Delahunt B, Egevad L, Srigley JR, Billis A, Bostwick DG, Camparo P, Cheng L, Clouston D, Denham J, Furusato B, Hartmann A, Jufe L, Kench J, Kenwright DN, Kristiansen G, Leite KRM, MacLennan GT, Merrimen J, Moch H, Oxley J, Pan CC, Paner G, Ro J, Sesterhenn IAM, Shanks J, Thunders M, Tsuzuki T, Wheeler T, Yaxley JW, Varma M. Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology 2020; 52:192-196.

200. Varma M, Srigley JR, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks JH, Tsuzuki T, van der Kwast T, Webster F, Grignon D.  Dataset for the reporting of urinary tract carcinoma – biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting  (ICCR). Modern Pathology 2020;33: 700-712.

199. Srigley JR, Delahunt B, Samaratunga H, Billis A, Cheng L, Clouston D, Evans A, Furusato B, Kench J, Leite K, MacLennan G, Moch H, Pan CC, Rioux-Leclercq N, Ro J, Shanks J, Shen S, Tsuzuki T, Varma M, Wheeler T, Yaxley J, Egevad L. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology 2019; 51:463-473.

198. Morgantetti G, Ng KL, Samaratunga H, Rhee H, Gobe GC, Wood ST. Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis. Transl Androl Urol 2019;8:S147-S155.

197. Ng KL, Ellis RJ, Samaratunga H, Morais C, Gobe GC, Wood ST. Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Transl Androl Urol 2019:8: S123-S137.

196. Delahunt B, Dagher J, Egevad L, Yaxley J, Varma M, Samaratunga HIs the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful? Am J Surg Pathol 2019: 43:1249-1252.

195. Delahunt B, Eble JN, Egevad L, Yaxley  J, Thunders M, Samaratunga H. Emerging entities of renal cell neoplasia. Surgical and Experimental Pathology 2019;10: 1-7.

194. Samaratunga H, Judge M, Delahunt B, Srigley J, Brimo F, Comperat E, Koch M, Lopez-Beltran A, Reuter V, Shanks J, Tsuzuki T, van der Kwast T, Varma M, Grignon D. Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Am J Surg Pathol 2019; 43:e1-e12.

193. Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int2019 124:401-407.

192. Lindh C, Kis L, Delahunt B, Samaratunga H, Yaxley J, Wiklund P, Clements M, Egevad L.PD-L1 Expression and Deficient Mismatch Repair in Ductal Adenocarcinoma of the Prostate. APMIS 2019 127:554-560.

191. Shanks JH, Srigley JR, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Tsuzuki T, van der Kwast T, Varma M, Grignon D. Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2019 75: 453-467.

190. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Varma M, Samaratunga H.Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology 2019 51:349-352.

189. Egevad L, Delahunt B, Yaxley J, Samaratunga H. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Varma M, Samaratunga H. Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology 2019 51:349-352.

188. Kristiansen A, Bergström R, Delahunt B, Samaratunga H, Guðjónsdóttir J, Grönberg H, Egevad L, Lindberg J. Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate 2019; 79:920-928.

187. Delahunt B, Egevad L, Samaratunga H, Kristiansen G. Intraductal carcinoma of the prostate: a critical re-appraisal.Virchows Arch 2019 474:525-534.

186. Egevad L, Delahunt B, Samaratunga H, Leite KR, Efremov G, Furusato B, Han M, Jufe L, Tsuzuki T, Wang Z, Hörnblad J, Clements M The International Society of Urological Pathology Education web-a web-based system for training and testing of pathologists Virchows Arch 2019; 474:577-584.

185. Becherel OJ, Fogel BL, Zeitlin SI, Samaratunga H, Greaney J, Homer H, Lavin MF. Disruption of Spermatogenesis and Infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2). Cerebellum 2019; 18:448-456.

184. Egevad L, Delahunt B, Yaxley J, Samaratunga HEvolution, controversies and the future of prostate cancer grading. Pathol Int 2019; 69:55-66.

183. Delahunt B, Eble JN, Egevad L, Samaratunga HGrading of renal cell carcinoma. Histopathology 2019;74: 4-17.

182. Berney DM, Comperat E, Feldman DR, Hamilton RJ, Idrees MT, Samaratunga H, Tickoo SK, Yilmaz A, Srigley JR. Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology 2019;74:171-183.

181. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Coughlin G, Dunglison N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Samaratunga H. Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology 2019;74:284-290.

180. Pokorny M, Kua B, Esler R, Yaxley J, Samaratunga H, Dunglison N, Gianduzzo T, Coughlin G, Holt R, Laing B, Ault D, Brown N, Parkinson R, Thompson L. MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. World J Urol 2019; 37:1263-1279.

179. Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L and Wong D. Outcomes of primary lymph node staging of prostate cancer with 68Ga-PET/CT PSMA scanning in intermediate and high risk prostate cancer, compared to histological correlation of pelvic lymph node pathology. Can a pre-operative 68Ga-PET/CT PSMA scan replace a PLND for prostate cancer staging? Journal of Urology 2019; 201: 815-820.

178. Delahunt B, Egevad L, Yaxley J, Samaratunga HThe current status of renal cell carcinoma and prostate carcinoma grading. Int Braz J Urol 2018;44:1057-1062.

177. Sina AA, Carrascosa LG, Liang Z, Grewal YS, Wardiana A, Shiddiky MJA, Gardiner RA, Samaratunga H, Gandhi MK, Scott RJ, Korbie D, Trau M. Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nat Commun 2018;9: 4915.

176. Moya L, Lai J, Hoffman A, Srinivasan S, Panchadsaram J, Chambers S, Clements JA, Batra J; Association Analysis of a Microsatellite Repeat in the TRIB1 Gene With Prostate Cancer Risk, Aggressiveness and Survival. Australian Prostate Cancer BioResource inc Samaratunga H. Front Genet 2018;9:428.

175. Koo KM, Wang J, Richards RS, Farrell A, Yaxley JW, Samaratunga H, Teloken PE, Roberts MJ, Coughlin GD, Lavin MF, Mainwaring PN, Wang Y, Gardiner RA, Trau M. Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction. ACS Nano 2018;12:8362-8371.

174. Coughlin GD, Yaxley JW, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Teloken P, Dunglison N, Williams S, Lavin MF, Gardiner RA. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018;19:1051-1060.

173. Ng KL, Del Vecchio SJ, Samaratunga H, Morais C, Rajandram R, Vesey DA, Wood ST, Gobe GC.  Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma? Pathology 2018; 50:504-510.

172. Matin F, Jeet V, Moya L, Selth LA, Chambers S; Australian Prostate Cancer BioResource, Clements JA, Batra J & Collaborators inc. Samaratunga HA Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer.Sci Rep 2018; 27;8:6653.

171. Egevad L, Samaratunga H, Delahunt B. Re: Comment on Egevad et al., ‘Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology 2018; 73:  361-362

170. Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hörnblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M. Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology 2018; 73:8-18.

169. Delahunt B, Egevad L, Srigley JR, Samaratunga HFuhrman grading is inappropriate for papillary renal cell carcinoma. World J Urol 2018 36: 1339-1340.

168. Lai J, Moya L, An J, Hoffman A, Srinivasan S, Panchadsaram J, Walpole C, Perry-Keene JL, Chambers S; Australian Prostate Cancer BioResource, Lehman ML, Nelson CC, Clements JA, Batra J. and  Collaborators inc. Samaratunga H microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness. Sci Rep 2017 4;7:16862.

167. Egevad L, Delahunt B, Kristiansen G, Samaratunga H, Varma M. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology 2018;50:60-73.

166. Lindh C, Delahunt B, Samaratunga H, Yaxley J, Gudjónsdóttir J, Clements M, Lindberg J, Egevad L. A Novel Technique for Biobanking of Large Sections of Radical Prostatectomy Specimens. Histopathology 2018: 72:481-489.

165. Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga HReconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 2018. ;36:15-20

164. Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, Stattin P, Egevad L. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology 2017 49:715-720

163. Delahunt B, Samaratunga H, Egevad L. The decline of medical publishing: the rise of the pseudo-journal.Pathology 2017; 49:673-674.

162. Samaratunga H, Delahunt B, Egevad E, Srigley JR, Yaxley J. Evolution of Gleason  grading. J Diagn Pathol 2017; 12: 5-11.

161. Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, Pan CC, Samaratunga H, Srigley JR, True L, Zhou M, Clements M, Delahunt B; ISUP Pathology Imagebase Expert Panel. Pathology Imagebase – A Reference Image Database for Standardization of Pathology. Histopathology 2017;71:677-685.

160Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, Samaratunga H. Clear cell renal cell carcinoma: Validation of WHO/ISUP grading. Histopathology 2017;71:918-925.

159. Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, Egevad L. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology 2017; 71:641-647.

158. Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes AM, Coughlin G, Stricker P.Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int 2017 120:673-681.

157. Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H; Australian Prostate Cancer BioResource, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA.Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Mol Oncol 2017 11:1307-1329.

156. Seipel AH, Whitington T, Delahunt B, Samaratunga H, Mayrhofer M, Wiklund P, Grönberg H, Lindberg J, Egevad L. Genetic Profile of Ductal Adenocarcinoma of the Prostate. Hum Pathol 2017 69:1-7.

155. Delahunt B, Egevad L, Samaratunga H, Varma M, Verrill C, Cheville J, Kristiansen G, Corbishley C, Berney DM. UICC drops the ball in the 8th edition TNM staging of urological cancers. Histopathology 2017; 71:5-11.

154. Egevad L, Samaratunga H, Delahunt B. Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. Int J Urol 2017; 24:286-287.

153. Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L. The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012. BJU International 2017;119:50-56.

152. Delahunt B, Grignon DJ, Samaratunga H, Srigley JR, Leite KR, Kristiansen G, Evans AJ, Kench JG, Egevad L.Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology & Laboratory Medicine 2017;141:182-183.

151. Egevad L, Samaratunga H, Srigley JR, Delahunt B.Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required.  Eur Urol 2017;71:e52-e53.

150. Roberts MJ, Richards RS, Chow CW, Doi SA, Schirra HJ, Buck M, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Prostate International 2016;4:97-102.

149. Delahunt B, Samaratunga H and Kenwright DN.  Histologic prognostic markers for renalcell neoplasia.  (Invited submission) Diagnostic Histopathology 2016; 22: 65-72.

148. Samaratunga H, Delahunt B, Yaxley J, Srigley JR, Egevad L. From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scandinavian Journal of Urology 2016;50:325-329.

147. Egevad L, Samaratunga H, Srigley JR, Delahunt B, Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. British Journal of Urology International 2016;118. E1-2.

146. Srigley JR, Delahunt B, Egevad L, Samaratunga H, Yaxley J, Evans AJ. One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal 2016;10: 339-341.

145. Egevad L, Samaratunga H, Srigley JR, Delahunt B. In Regard to Zietman et al. Int J Radiat Oncol Biol Phys 2016 1;96:1126-1127.

144. Egevad L, Samaratunga H, Srigley JR, Delahunt B. New Gleason grading system: Statement from the editors of 6 journals. Urol Oncol 2016;34:479-480.

143. Egevad L, Samaratunga H, Srigley JR, Delahunt B. Reply by the Authors. Urology 2016; 96:179-180.

142.Egevad L, Samaratunga H, Srigley JR and Delahunt B.  Consensus guidelines for reporting prostate cancer Gleason grade.  Journal of Urology 2016; 196:  1321-1323.

141. Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J. Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. British Journal of Urology International 2017 120:56-60.

140. Rhee H, Ng KL, Tse BW, Yeh MC, Russell PJ, Nelson C, Thomas P, Samaratunga H, Vela I, Gobe G, Wood S. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology 2016;48:613-616.

139. Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Dunglison N, Carter R, Williams S, Payton DJ, Perry-Keene J, Lavin MF, Gardiner RA. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016 : 10;388(10049):1057-1066.

138, Roberts MJ, Yaxley JW, Coughlin GD, Gianduzzo TR, Esler RC, Dunglison NT, Chambers SK, Medcraft RJ, Chow CW, Schirra HJ, Richards RS, Kienzle N, Lu M, Brereton I, Samaratunga H, Perry-Keene J, Payton D, Oyama C, Doi SA, Lavin MF, Gardiner RA. Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.Contemporary Clinical Trials 2016; 50:16-20.

137. Seipel AH, Delahunt B, Samaratunga H, Egevad L. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology 2016;48:398-405.

136. Egevad L, Delahunt B, Srigley JR, Samaratunga HInternational Society of Urological Pathology (ISUP) grading of prostate cancer – An ISUP consensus on contemporary grading. Acta Pathologica Microbiologica, et Immunologica Scandinavica 2016;124:433-435.

135. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Reply: Gleason and Fuhrman no longer make the grade. Histopathology 2016;69:341-342.

134. Delahunt B, Egevad L, Grignon DJ, Srigley JR, Samaratunga HProstate cancer grading: recent developments and future directions. British Journal of Urology International 2016;117 Suppl 4:7-8.

133. Egevad L, Delahunt B, Evans AJ, Grignon DJ, Kench JG, Kristiansen G, Leite KR, Samaratunga H, Srigley JR. International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. American Journal of Surgical Pathology 2016; 40:858-861.

132. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR.Gleason and Fuhrman no longer make the grade. Histopathology 2016;68:475-481.

131. Ng KL, Morais C, Bernard A, Saunders N, Samaratunga H, Gobe G, Wood S. A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. Journal of Clinical Pathology 2016;69:661-671.

130. Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Compérat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ. Gleason Grade 4 Prostate Adenocarcinoma Patterns: An Inter-observer Agreement Study among Genitourinary Pathologists.Histopathology 2016;69:441-449.

129. Gobe GC, Ng KL, Small DM, Vesey DA, Johnson DW, Samaratunga H, Kimberley O, Wood S, Barclay JL, Rajandram R, Li L, Morais C. Decreased Apoptosis Repressor with Caspase Recruitment Domain Confers Resistance to Sunitinib in Renal Cell Carcinoma through Alternate Angiogenesis Pathways. Biochemical and biophysical research communications 2016; 22;473:47-53.

128. Seipel AH, Samaratunga H, Delahunt B, Wiklund P, Clements M, Egevad L. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2016;124:263-270.

127. Egevad L, Delahunt B, Samaratunga H, Srigley JR. Utility of Reporting the Percentage of High-grade Prostate Cancer. European Urology 2016 ;69:599-600.

126. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee including Samaratunga H. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. American Journal of Surgical Pathology 2016;40:244-252.

125. Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology 2016;11:345-351.

124. Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Fergusson P, Nacey JN. Pleomorphic Giant Cell Carcinoma of the Urinary Bladder: An Extreme Form of Tumour De-differentiation. Histopathology 2016;68:533-540.

123. Samaratunga H, Delahunt B. Mesenchymal tumors of adult kidney. Seminars in  Diagnostic Pathology 2015;32:160-171.

122. Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology 2015;47:1-3.

121. Matsika A, Srinivasan B, Day C, Mader SA, Kiernan DM, Broomfield A, Fu J, Hooper JD, Kench JG, Samaratunga HCancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2.  Pathology 2015; 47:622-628.

120. Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I, Johannsen S, Egevad L, Yaxley J. The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology 2015;47:515-519.

 119. Scott S, Samaratunga H, Chabert C, Breckenridge M, Gianduzzo T. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis. British Journal of Urology International 2015;116 Suppl 3:26-30.

118. Roberts MJ, Chow CW, Schirra HJ, Richards R, Buck M, Selth LA, Doi SA, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Prostate 2015 1;75:539-549.

117. Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology.; UK ProtecT Study Collaborators inc Samaratunga H; PRACTICAL Consortium. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.Cancer epidemiology, biomarkers & prevention 2015;24:1121-1129.

116. Srigley JR, Delahunt B, Egevad L, Samaratunga H, Evans AJ. Optimising pre-analytical factors affecting quality of prostate biopsies: the case for site specific labelling and single core submission. Pathology 2014;46:579-580.

115. Rioux-Leclercq N, Algaba F, Amin M, Argani P, Billis A, Bonsib S, Cheng L, Cheville J, Eble J, Egevad L, Epstein J, Grignon D, Hes O, Humphrey P, Maggi-Galluzzi C,  Martignoni G, McKenney J, Merino M, Moch H, Montironu R, Netto G, Reuter V, Samaratunga H, Shen S, Srigley J, Tamboli P, Tan P, Tickoo S, Trpkov K, Zhou M, Delahunt B, Comperat E. Les tumeurs rénales : recommandations de la conférence de consensus de l’International Society of Urologic Pathology (ISUP) Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations. Annales De Pathologie 2014;34:448-461.

114. Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archives 2014;465:623-628.

113. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond E. The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists and the Prostate Cancer Foundation. Archives of Pathology & Laboratory Medicine 2014;138:1387-405.

112. Delahunt B, Samaratunga H, Martignoni G, Srigley JR, Evans AJ, Brunelli M. Percutaneous Renal Tumour Biopsy. Histopathology 2014;65:295-308.

111. Samaratunga H, Gianduzzo T, Delahunt B. The ISUP system of staging, grading and classification of renal cell neoplasia. Journal of Kidney Cancer and VHL 2014;  1:26-39.

110. Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC and Wood ST. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? Journal of Clinical Pathology 2014;67:97-104.

109. Gardiner RA, Chambers SK, Williams SG, Yaxley J, Samaratunga H, Frydenberg M  Prostate Cancer – Part One: Detection. In : De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 2014 Jun 2.

108. Perry-Keene J, Ferguson P, Samaratunga H, Nacey JN, Delahunt B. Effective maybe, but is it cost-effective? A reply. Histopathology 2014;65:729-730.

107. Klopfer K, Delahunt B, Adamson M, Samaratunga H. Value of Uroplakin III in Distinguishing Variants of Primary Bladder Urothelial Carcinoma from Malignancy Metastatic to the Urinary Bladder. Anticancer Research 2014;34:6779-6784.

106. Seipel AH, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, Grönberg H, Egevad L. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Archives 2014;465:559-565.

105. Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S and Egevad L. Diagnostic Criteria for Ductal Adenocarcinoma of the Prostate. Interobserver Variability among 20 Expert Uropathologists. Histopathology 2014;65:216-227.

104. Samaratunga H, Delahunt B, Yaxley J, Perry-Keene J, Lamb DS, Srigley JR, Egevad L and Nacey JN. Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology 2014;46:11-14.

103. Gardiner RA, Coughlin GD, Yaxley JW, Dunglison NT, Occhipinti S, Younie SJ, Carter RC, Williams SG, Medcraft RJ, Samaratunga HM, Perry-Keene JL, Payton DJ, Lavin MF and Chambers SK. A progress report on a prospective randomised trial of open and robotic prostatectomy. European Urology 2014;65:512-515.

102. Perry-Keene J, Ferguson P, Samaratunga H, Nacey JN and Delahunt B. Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases. Histopathology 2014;65:729-730.

101. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR and the members of the ISUP Renal Tumor Panel. Handling and Staging of Renal Cell Carcinoma: The International Society of Urological Pathology Consensus (ISUP) Conference Recommendations.American Journal of Surgical Pathology 2013; 37:1505-1517.

100. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H and the ISUP Renal Tumor Panel including Samaratunga HRenal tumors: diagnostic and prognostic biomarkers. American Journal of Surgical Pathology 2013;37:1518-1531.

99. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel including Samaratunga HThe International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. American Journal of Surgical Pathology 2013;37:1490-1504.

98. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P and the ISUP Renal Tumor Panel including Samaratunga HThe International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology 2013;37:1469-1489.

97. Compérat E, Camparo P, Srigley J, Delahunt B, Egevad L and ISUP Consensus Working Group inc. Samaratunga HInternational Society of Urological Pathology (ISUP) Consensus Conference on handling and H of radical prostatectomy specimens]. Annales De Pathologie 2013;33:155-161.

96.   Samaratunga H, Martignoni G, Egevad L and Delahunt B. Premalignant lesions of the urinary bladder. Pathology 2013;45:243-50.

95. Samaratunga H and Delahunt B. Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology 2012;44:407-18.

94. Delahunt B, Miller RJ, Srigley JR, Evans AJ and Samaratunga HGleason grading: past, present and future.Histopathology 2012;60:75-86.

93. Samaratunga H, Samaratunga D, Dunglison N, Perry-Keene J, Nicklin J and Delahunt B. Alpha-fetoprotein-producing Carcinoma of the Renal Pelvis Exhibiting Hepatoid and Urothelial Differentiation. Anticancer Research 2012;32:4987-4991.

92. Bennett NCHooper JDLambie DLee CSYang TVesey DASamaratunga HJohnson DW and Gobe GC. Evidence for steroidogenic potential in human prostate cell lines and tissues. American Journal of Pathology 2012;181:1078-1087.

91. Lose FSrinivasan SO’Mara TMarquart LChambers SGardiner RAAitken JFthe Australian Prostate Cancer BioResource, Collaborators inc Samaratunga H Spurdle ABBatra J and Clements JA. Genetic Association of the KLK4 Locus with Risk of Prostate Cancer. PLoS One 2012;7:e44520.

90. Ranaweera MSamaratunga HDuffy DKlopfer KBrunelli MMartignoni GDelahunt B. Tertiary Gleason pattern 5 on needle biopsy predicts greater tumour volume on radical prostatectomy. Pathology 2011;43:693-696.

89. Delahunt BSika-Paotonu DBethwaite PBWilliam Jordan TMagi-Galluzzi CZhou MSamaratunga H and Srigley JR. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. American Journal of Surgical Pathology 2011;35:1134-1139.

88. Samaratunga H, Yaxley J, Delahunt B. Ductal adenocarcinoma of the prostate-reply. Human Pathology 2011; 42: 605-607.

87. Kench JGClouston DRDelprado WEade TEllis DHorvath LGSamaratunga HStahl JStapleton AMEgevad LSrigley JR Delahunt B. Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology 2011;43:410-419.

86. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B and Egevad L; The ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology 2011;24:6-15.

85. Egevad LSrigley JRDelahunt BAmin, MBerney DMBillis ACheng LEpstein JEvans AGrignon DHumphrey PMagi-Galluzzi CMontironi RSamaratunga HTan PHTrue LVan Der Kwast TWheeler TInternational society of urological pathology consensus conference on handling and staging of radical prostatectomy specimens Advances in Anatomic Pathology 2011; 18: 301-305.

84. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; the ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathology 2011;24:16-25.

83. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI. The ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology 2011;24:48-57.

82. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA, the ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Modern Pathology 2011;24:26-38.

81. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; the ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology 2011;24:39-47.

80.Compérat ERoupret MYaxley JReynolds JVarinot JOuzaïd ICussenot O and Samaratunga H. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 2010;42:650-654.

79. Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA Marshall VR, Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H,  Clements JA, Risbridger GP, Sutherland RL, Tilley WD; and Horsfall DJ for the Australian Prostate Cancer BioResource Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer epidemiology, biomarkers & prevention2010;19:1755-1765.

78. Delahunt B, Lamb DS, Srigley JR, Murray JD, Wilcox C, Samaratunga H, Atkinson C, Spry NA, Joseph D and Denham JW. Gleason scoring: A comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point. Pathology 2010;42:339-343.

77. Samaratunga H, Samaratunga D, Perry-Keene J, Adamson M, Yaxley J and Delahunt B. Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology 2010 42:330-333.

76. Whitbread AKVeveris-Lowe TLDong YTan OLGardiner RSamaratunga HMNicol DL and Clements JA. Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry 2010;391:461-466.

75. Gobbo S, Eble JN, Delahunt B, Grignon DJ, Samaratunga H, Martignoni G, Zhang S, Wang M, Brunelli M, Cossu-Rocca P, Cheng L. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical and cytogenetic profiles American Journal of Surgical Pathology 2010;34:620-626.

74. Aydin H, Zhang J, Samaratunga H, Tan N, Magi-Galluzzi C, Klein E, Jones JS and Zhou M. Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. British Journal of Urology International 2010;105:476-480.

73. Samaratunga H, Duffy D, Yaxley J and Delahunt B Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Human Pathology 2010; 41:281-285.

72. Samaratunga H, Epstein JI. Genitourinary pathology in the new millennium. Pathology 2010;42:317-318.

71. Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, Samaratunga H, Lavin MF and Gardiner RA New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009;4:e4995.

70. Samaratunga H and Delahunt B.  Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol 2008;30:237-246.

69. Samaratunga H and Epstein JI. What is the molecular pathology of low-risk prostate cancer? World J Urol 2008;26:431-436.

68. Samaratunga H and Fitzpatrick P.  Cellular angiofibroma of the scrotum. Pathology 2008;40:330-333.

67. Cheng L,Gobbo S, Eccher A, Eble J, Delahunt B, Grignon D, Samaratunga H et al. Hybrid tumors in renal oncocytosis: the missing link between oncocytoma and chromophobe renal cell carcinoma? Virchows Archives 2008; 452: S12 -S13.

66. Ramsay AJ, Reid JC, Adams MN, Samaratunga H, Dong Y, Clements JA and Hooper JD. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry 2008;389:653-668.

65. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF and Gardiner RA. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. British Journal of Cancer 2008 ;5;99:491-501.

64. Willems AJ, Dawson S, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ; kConFab Investigators..Loss of heterozygosity at the BRCA2 locus detected by Multiplex ligation-Dependent Probe Amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clinical Cancer Research 2008; 15;14:2953-2961.

63. Dong Y, Matigian N, Harvey TJ, Samaratunga H, Hooper JD and Clements JA. Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biological Chemistry 2008;389:99-109.

62. Kaushal A, Myers SA, Dong Y, Lai J, Tan OL, Bui LT, Hunt ML, Digby MR, Samaratunga H, Gardiner RA, Clements JA and Hooper JD. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus. Prostate 2008 1;68:381-399.

61. Samaratunga H and Letizia B. Prostatic ductal adenocarcinoma presenting as a small prostatic urethra polyp; a clinicopathological analysis of 8 cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethra polyp. Pathology 2007;39:476-481.

60. Samaratunga H, Yaxley J, Kerr K, McClymont K and Duffy D. The significance of a minute focus of adenocarcinoma on prostate needle biopsy. Urology 2007; 70: 299-302.

59. Samaratunga H. Editorial comment on: Inflammatory atrophy on prostate needle biopsies: Is there topographical relationship to cancer.  International Brazilian Journal of Urology 2007; 33: 363.

58. Samaratunga H, Gardiner RA, Yaxley J and Brown I. Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry and clinical significance. Analytical and Quantitative Cytology and Histology 2006; 28:104-110.

57. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A and Lucia MS. A working group classification of focal prostate atrophy lesions. American Journal of Surgical Pathology 2006; 30:1281-1291.

56. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL and the ISUP Grading Committee (Inc. Samaratunga HThe 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology 2005; 29: 1228-1242.

55. Gardiner RA, Landers K, Burger MJ et al inc. Samaratunga H. Claudin 4: A new therapeutic target for prostate cancer. British Journal of Urology International 2005; 95:1.

54. Dong Y, Bui LT, Odorico DM, Tan OL, Myers SA, Samaratunga H, Gardiner RA, Clements JA. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.  Endocrine Related Cancer 2005;12:875-889.

53. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF and Gardiner RA. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005;114:950-956.

52. Samaratunga H, Fairweather P and Purdie D. Significance of stromal reaction patterns in invasive urothelial carcinoma. American Journal of Clinical Pathology 2005;123:851-857.

51. Samaratunga H and Khoo K.  Micropapillary urothelial carcinoma of the urinary bladder: Histopathology2004;45:55-64.

50. McCulloch DR, Akl P, Samaratunga H , Herington AC and Odorico DM. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clinical Cancer Research 2004 1;10:314-323.

49. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA.  Human Kallikrein 4 (KLK 4) is highly expressed in serous ovarian carcinomas.  Clinical Cancer Research 2003;9:1710-1720.

48. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF and Gardiner RA.  Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer: International Journal of Cancer 2002; 10;100:228-237.

47. Samaratunga H, Makarov DV and Epstein JI.  Comparison of WHO/ISUP and WHO Classification of non-invasive papillary urothelial neoplasms for risk of progression: Urology 2002;60:315-319.

46. Epstein JI, Makarov DV and Samaratunga H. Comparison of WHO/ISUP and WHO Classification of non-invasive papillary urothelial neoplasms (pTa) for risk of progression. Journal of Urology 2002; 16: 190-191.

45. Samaratunga H, Weedon D, Musgrave N and McCallum N. Atypical Presentation of Herpes Simplex (Chronic Hypertrophic Herpes) in a patient with HIV infection. Pathology 2001; 33:530-533.

44. Samaratunga H, Clarke B, Owen L, Bryson G and Swanson C.  Phyllodes tumours of the breast: correlation of nucleolar organizer regions with histopathological malignancy grading, flow cytometric.  DNA analysis and clinical outcome.  Pathology International 2001;51:866-873.

43. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM and McManus ME.  Localization of N-acetyl Transferases NATI and NAT2 in human tissue.  Toxicological Sciences 2000;54:19-29.

42. Samaratunga H, Spork MR and Cooritz D.  Sclerosing sertoli cell  of tumor of testis  Journal of Urological Pathology. 2000;12: 39-50.

41. Samaratunga H and Williamson R.  Metastatic foamy gland carcinoma of prostate.  Journal of Urological Pathology. 2000; 12: 53-54.

40. Horwood KR, Samaratunga H Primary vaginal non-Hodgkin’s lymphoma after radiotherapy for Hodgkin’s disease.Australian and New Zealand journal of medicine. 2000;30:404-405.

39. Samaratunga H.  Cervical adenoid basal epithelioma. The American journal of surgical pathology 1999; 23: 1308-1309.

38. Clements JA, Rohde P, Allen V, Hyland V, Samaratunga ML, Tilley W, Lavin M and Gardiner RA.  Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. Journal of Urology 1999; 161: 1337-1343.

37.  Kotlovsky A, Sillar D, Samaratunga M and Gardiner RA.  Evaluation of myectonized partial thickness ileum in experimental bladder augmentation:  Australian and New Zealand journal of Surgery 1998; 68: 587-591.

36. Samaratunga H and Williamson R.  Metastatic foamy gland carcinoma of the prostate. A potential diagnostic pitfall. Journal of Urological Pathology 1998; 9:155-161.

35.  Teng HS, Hardie IR, Samaratunga MLTH and Gardiner RA.  Experimental pyeloureterectomy and calyceal neck transection with autotransplantation and bladder advancement. British Journal of Urology 1998; 82: 877-881.

34. McCrystal D, O’Loughlin B and Samaratunga H.  Mesenteric panniculitis; a mimic of malignancy. Australian and New Zealand Journal of Surgery 1998 68: 237-239.

33. Samaratunga H, Searle JW and Hudson N.  Non-rabies Lyssavirus human encephalitis from fruit bats.  Australian bat Lyssavirus (Pteropid Lyssavirus) infection.  Neuropathology and Applied Neurobiology 1998; 24: 331-335.

32. Hooper PT, Lunt RA, Gould A, Samaratunga H, Hyatt AD, Westbury HA, Gleeson LJ and Murray PK.  A new Lyssavirus – The first endemic Rabies-related virus recognised in Australia.  Bulletin de L’Institute Pasteur; Research in Infectious Diseases 1997; 95: 209-218.

31. Samaratunga H and Singh M. Distribution pattern of basal cells detected by Cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma.  American Journal of Surgical Pathology 1997; 21(4): 435-440.

30. Sillar DB, Samaratunga H, O’Brien M, Kotlovsky A, Mundy AR and Gardiner RA. Intussuscepted partial thickness ileal valve (IPI-valve) incontinent diversion diversion. European Urology 1997; 31: 102-107.

29. Samaratunga H, Perry-Keene D and Apel RA. Primary lymphoma of pituitary gland. Endocrine Pathology 1997; 8: 335-341.

28. Gardiner RA, Samaratunga MLTH, Rhoder P, Clements JA, Hyland V and Lavin MF.  Malignant cytological washings from radical prostatectomy specimens; a possible mechanism for local recurrence of prostate carcinoma following surgical treatment of organ confined disease. Journal of Urology 1997; 158: 889.

27. Gardiner RA, Samaratunga MLTH, Gwynne RA, Clague A, Seymore GJ and Lavin MF. Abnormal prostatic cells in ejaculates from men with prostatic cancer – a preliminary report:  British Journal of Urology 1996; 78: 414-418.

26. Kotlovsky A, Samaratunga MLTH and Gardiner RA.  Myectomised partial thickness bowel in urinary reconstruction.  Australian and New Zealand journal of Surgery 1996; 66: 390.

25. Samaratunga H, Searle J and O’Loughlin B. Intravascular fasciitis:  A case report and review of the literature.  Pathology 1996; 28: 8-11.

24. Samaratunga H, Searle J and O’Loughlin B. Nodular fasciitis and related pseudosarcomatous proliferative lesions of skin and soft tissue. Australian and New Zealand Journal of Surgery 1996; 66: 22-25.

23. Calvert ML, Robertson I and Samaratunga H. Mango dermatitis: allergic contact dermatitis to Mangifern indica.  Australian Journal of Dermatology 1996 37: 59-60.

22. Samaratunga H. Carcinoma in mesonephric remnants: American Journal of Surgical Pathology 1995; 19: 1218-1219.

21. Devine PL, Walsh MD, McGuckin MA, Quin RJ, Hohn BG, Clague A, Samaratunga H. Prostate – specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. International Journal of Biological Markers 1995;10: 221-225.

20. Singh M, Samaratunga H, Wright C and Guandalini I. Prostatic carcinoma metastatic to the testis simulating intratubular germ cell neoplasia. British Journal of Urology 1995; 75: 803-804.

19. Samaratunga H, Kanowski P, O’Loughlin B, Walker N and Searle J. Adenocarcinoma of the rete testis with intratubular invasion of the testis. Journal of Urological Pathology 1994; 2: 291-300.

18. Walsh MD, Hohn BG, Thong W, Devine PL, Gardiner RA, Samaratunga MLTH and McGuckin MA. Mucin expression by transitional cell carcinomas of the bladder. British Journal of Urology 199473: 256-262.

17. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga MLTH, Seymore GJ and Lavin MF. Immunohistologic expression of P53 in primary PT1 transitional cell bladder cancer does not relate to tumour progression.  British Journal of Urology 1994; 73: 526-532.

16. Samaratunga H, Beresford A and Davison A. Squamous-cell carcinoma in situ involving mesoneoplasic remnants – A potential diagnostic pitfall:  The American journal of surgical pathology 1994;18: 1265-1269.

15. Samaratunga H, Searle J, Cominos D and LeFevre I. Cerebral metastasis of an atrial myxoma mimicking an epithelioid hemangioendothelioma: American Journal of Surgical Pathology 1994; 18: 107-111.

14. Samaratunga H, Cox N and Wright RG. Human papilloma virus DNA in glandular lesions of the uterine cervix.  Journal of clinical pathology 1993;46:718-721.

13. Apel R and Samaratunga H. Lymph node pseudotumor - American Journal of Surgical Pathology 1993; 17: 91-93.

12. Samaratunga H, Hohn BG, Walsh M, Gardiner RA, Devine PL and McGuckin MA.Mucin inclusions in urothelial carcinomas. Human Pathology1993; 24: 929-930.

11. Gardiner RA, Samaratunga MLTH, Walsh MD, Seymore GL and Lavin MF. An Immunohistochemical Demonstration of C-erb-B2 Oncoprotein Expression in Primary Urothelial Bladder Cancer. Urology Research 1992; 20: 117-120.

10. Wright RG, Samaratunga MLTH and Jaworski R. Absence of Human Papilloma Virus in Cervical Adenocarcinoma. Journal of Clinical Pathology 1992; 45: 271.

9. Samaratunga H and Wright G. Value of Fine Needle Aspiration Biopsy Cytology in the Diagnosis of Discrete Hepatic Lesions Suspicious for Malignancy. Australian and New Zealand journal of  Surgery 1992; 62: 540-544.

8. Samaratunga H, Strutton G, Wright RG and Hill B. Squamous cell carcinoma arising in a case of vulvitis granulomatosa or vulval variant of Melkersson-Rosenthal syndrome. Gynecologic Oncology 1991; 41: 263-269.

7. Nicklin JL, Wright RG, Bell JR, Samaratunga MLTH, Cox NC and Ward BG. A Clinicopathologic Study of Adenocarcinoma in Situ of the Cervix.  The influence of cervical HPV infection and other factors, and the role of conservative surgery.  Australian and New Zealand journal of  Obstetrics and Gynaecology 1991; 31(2):179-183.

6. Gardiner RA and Samaratunga MLTH. Application of the Invaginated Sleeve Technique to form a Continent Ileal Urostomy.  British Journal of Urology 1990; 65: 457-461.

5.  Gardiner RA, Mills G, Rivory L and Samaratunga MLTH. Evaluation of a Bladder Advancement Extension Graft Technique. British Journal of Urology 1990 66: 606-612.

4. Samaratunga H and Cox N. Evaluation of an In Situ Hybridization Kit for the Diagnosis of Cytomegalovirus Infection: Australian Journal of Medical Laboratory Science 1990; 11: 11-14.

3. Gardiner RA, Samaratunga MLTH. Development of the Invaginated Sleeve Technique for Continent Cystostomies in Dogs.  British Journal of Urology 1989; 63: 276-280.

2. Gardiner RA, Samaratunga MLTH. Flap valve cystostomy using an invaginated sleeve of mucosa, lamina propria and superficial muscle. British Journal of Urology 1988; 62: 473-475.

1. Faoagali JL, DeBuse P, Strutton GM, Samaratunga H. A Case of Rabies:  The Medical Journal of Australia 1988; 149: 11-12.

BOOKS

28. Samaratunga H, Clouston D, Delahunt B, Delprado W, Grimes D, Kench J, Perry   Keane J and Yaxley J.  urinary tract carcinoma – transurethral resection and biopsy   structured reporting protocol  (1st edition 2018. Royal College of Pathologists of Australasia. Sydney, Australia. pp 64.  ISBN 978-1-74187-704-5, 2018.

27. Samaratunga H, Clouston D, Delahunt B, Delprado W, Grimes D, Kench J, Perry   Keane J and Yaxley J.  Carcinoma of the urethra structured reporting protocol (urethrectomy) 1st edition 2018. Royal College of Pathologists of Australasia. Sydney, Australia. pp 64.  ISBN 978-1-74187-704-5, 2018

26. Samaratunga H, Clouston D, Delahunt B, Delprado W, Grimes D, Kench J, Perry   Keane J and Yaxley J.  Carcinoma of the renal pelvis and ureter structured reporting protocol (nephroureterectomy and ureterectomy) 1st edition 2018 Royal College of Pathologists of Australasia. Sydney, Australia. pp 64.  ISBN 978-1-74187-704-5, 2018

25. Samaratunga H, Clouston D, Delahunt B, Delprado W, Grimes D, Kench J, Perry   Keane J and Yaxley J.  Urinary Bladder Carcinoma Structured Reporting Protocol (Radical Cystectomy, Partial Cystectomy, Cystoprostatectomy). 2nd Edition. 2018 Royal College of Pathologists of Australasia. Sydney, Australia. pp 64.  ISBN 978-1-74187-704-5, 2018.

24. Clouston D, Delahunt B, Davis I, Delprado W, See A, Kench J, Lawrentschak N and Samaratunga H.  Carcinoma of the Penis Structured Reporting Protocol.  Royal College of Pathologists of Australasia:  Sydney, Australia.  pp 81.  ISBN 978-1-76000-923-6, 2018.

23. Clouston D, Delahunt B, Davis I, Delprado W, See A, Kench J, Lawrentschak N and Samaratunga H.  Neoplasia of the Testis- Retroperitoneal Lymphadenectomy Structured  Reporting Protocol.  Royal College of Pathologists of Australasia:  Sydney, Australia.  pp 59. ISBN 978-1-76000-924-3, 2018.

22.Clouston D, Delahunt B, Davis I, Delprado W, See A, Kench J, Lawrentschak N and  Samaratunga H.  Neoplasia of the Testis – Orchidectomy Structured Reporting Protocol. Royal College of Pathologists of Australasia:  Sydney, Australia.  pp 72.  ISBN 978-1-76000-925-0, 2018.

21. Grignon D, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks J, Tsuzuki  T, van der Kwast  T, Varma  M, Srigley JR. (2018) Carcinoma of the Urethra, Histopathology Reporting Guide, Urethrectomy Specimen, 1st Edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-15-6

20. Grignon D, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks J,  Tsuzuki  T, van der Kwast  T, Varma  M, Srigley JR. (2018) Carcinoma of the Renal Pelvis and Ureter, Histopathology Reporting Guide, Nephroureterectomyand Ureterectomy Specimen, 1st Edition.  International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-16-3

19. Grignon D, Brimo F, Comperat  E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks J,  Tsuzuki  T, van der Kwast  T, Varma  M, Srigley JR. (2018) Carcinoma of the Bladder, Histopathology Reporting Guide, 1st Edition.  International  Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-13-2

18. Grignon D, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks J,  Tsuzuki  T, van der Kwast  T, Varma  M, Srigley JR. (2018) Urinary Tract Carcinoma, Histopathology Reporting Guide, Biopsy and Transurethral Resection Specimen, 1st Edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-14-9

17. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Horvath L, Rasiah K, Samaratunga H and Stahl J.  Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol. Third edition.  Royal College of Pathologists of Australasia:  Sydney, Australia. Pp 81.  ISBN 978-1-76000-919-4, 2018.

16. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Horvath L, Rasiah K, Samaratunga H and Stahl J.  Prostate Cancer (Core/Needle Biopsy) Structural Reporting Protocol. Second Edition.  Royal College of Pathologists of Australasia:  Sydney, Australia. pp 65.  ISBN 978-1-76000-920-5, 2018.

15. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Horvath L, Rasiah K,  Samaratunga H and Stahl J.  Prostate Cancer (Transurethral Resection and Enucleation) Structural Reporting  Protocol. Second Edition.  Royal College of Pathologists of Australasia: Sydney, Australia.  pp 53.  ISBN 978-1-76000-918-2, 2018.

14. Delahunt B, Clouston D, Delprado W, O’Donnell A, Kench J, Samaratunga H and Wood S. Carcinoma of Renal Tubular Origin (Excision Specimens) Structured Reporting Protocol. Second Edition. Royal College of Pathologists of Australasia:  Sydney, Australia.  pp 60.  ISBN 978-1-76000-921-2, 2018.

13. Delahunt B, Clouston D, Delprado W, O’Donnell A, Kench J,  Samaratunga H and Wood S.Renal Biopsy for Tumour Structured Reporting Protocol. Royal College of Pathologists of Australasia:  Sydney, Australia.  pp 46.  ISBN 978-1-76000-922-2, 2018.

12. Delahunt B, Charles A, Clouston D, Delprado W, O’Donnell A, Eade T, Kench J,  Lau H and Samaratunga H.  Renal Parenchymal Malignancy (Renal Cell Carcinoma) Structured Reporting Protocol. 2nd Edition. 2017. Royal College of Pathologists of Australasia.Sydney, Australia

11. Clouston D, Delahunt B, Davis I, Delprado W, See A, Kench J, Lawrentschak N and Samaratunga H.  Neoplasia of the Testis – Orchidectomy Structured Reporting Protocol.  Royal College of Pathologists of Australasia:  Sydney, Australia.  pp 72.  ISBN 978-1-76000-925-0, 2018

10. Berney DM, Idrees MT, Tickoo SK, Yilmaz A, Comperat E, Samaratunga H, Feldman DR, Hamilton RJ, Srigley JR. (2017) Neoplasia of the Testis, Retroperitoneal Lymphadenectomy, Histopathology Reporting Guide 1st edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-08-8

9. Berney DM, Idrees MT, Tickoo SK, Yilmaz A, Comperat E, Samaratunga H, Feldman DR, Hamilton RJ, Srigley JR. (2017) Neoplasia of the Testis, Retroperitoneal Lymphadenectomy, Histopathology Reporting Guide 1st edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-08-8.

8. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Horvath L, Samaratunga H and Stahl J.  Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol.  Second edition.  Royal College of Pathologists of Australasia:  Sydney, Australia.  pp75.  ISBN 9787-1-74187-701-4, 2014

7. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Ellis D, Horvath L, Samaratunga H, Stahl J and Stapleton A.  Prostate Cancer (Core/Needle Biopsy) Structured Reporting Protocol. 1st Edition. 2014. Royal College of Pathologists of Australasia, Sydney, Australia. ISBN, 978-1-74187-474-7.

6. Samaratunga H, Clouston D, Delahunt B, Delprado W, Grimes D, Kench J, Perry   Keane J and Yaxley J.  Urinary Bladder Carcinoma Structured Reporting Protocol (Radical Cystectomy, Partial Cystectomy, Cystoprostatectomy). 1st Edition. 2012 Royal College of Pathologists of Australasia. Sydney, Australia. ISBN 978-1-74187-704-5.

5. Clouston D, Charles A, Delahunt B, Davis I, Delprado W, Eade T, Kench J, Lawrentschuk  N and Samaratunga H.  Testicular Tumours Structured Reporting  Protocol. 1st Edition. 2011. Royal College of Pathologists of Australasia. Sydney, Australia. ISBN 978-1-74187-702-1.

4. Delahunt B, Charles A, Clouston D, Delprado W, O’Donnell A, Eade T, Kench J, Lau H and Samaratunga H.  Renal Parenchymal Malignancy (Renal Cell Carcinoma) Structured Reporting Protocol. 1st Edition. 2011. Royal College of Pathologists of Australasia.Sydney, Australia. ISBN 978-1-74187-655-0.

3. Delahunt B, Galletly DC, Samaratunga H, Koleda CB, Bethwaite PB. Manual of the Use and Interpretation of Pathology. 5th Edition. 2009. Royal College of Pathologists of Australasia, Sydney, Australia. ISSN 1449-8219.

2. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Ellis D, Horvath L, Kneebone A, Samaratunga H, Stahl J and Stapleton A.  Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol.  1st Edition. 2010. Royal College of Pathologists of Australasia, Sydney, Australia ISBN 978-1-74187 – 462-4.

1. Samaratunga H, Epstein JI (Editors) Prostate Pathology: International Academy of Pathology Slide Seminar Series. 1st Edition 2004; Knowledge Books, Australia; ISBN 1920824 91-x.

 

BOOK CHAPTERS

 19. Egevad L, Epstein JI, Hameed O, Humphrey PA, Samaratunga H.  Ductal adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Moch H, Humphrey P, Ulbright T, Reuter V. 4th edition. 2016. IARC Press.  Zurich. ISBN 978-92-832-2437-2.

18. Humphrey PA, Amin MB, Berney DM, Billis A, Cao D, Cheng L, Delahunt B, Egevad L, Epstein JI, Fine SW, Grignon DJ, Kristiansen G, Lopez-Beltran A, Magi-Galuzzi C, Netto GJ, Rubin MA, Samaratunga H, Srigley JR, True LD, Tsuzuki T, Van der Kwast T. Acinar adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization  Classification of Tumors Editors: Moch H, Humphrey P, Ulbright T, Reuter V. 4th edition.  IARC Press. Zurich. ISBN 978-92-832-2437-2.

17. Delahunt B, Samaratunga H. Chapter 4. Pathology of the Renal Pelvis and Ureter. Urological Pathology. Editors: Amin MB, Grignon DJ, Srigley JR, Eble JN,. 1st Edition. 2014. Lippincott, Williams and Wilkins: Philadelphia. ISBN 978-0781782814.

16. Samaratunga H. Urothelial carcinoma with syncytiotrophoblastic giant cells. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012. Elsevier Philadelphia. ISBN:978-1-4377-2523-0.

15. Samaratunga H. Metastatic carcinoma to the bladder. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition. 2012.  Elsevier Philadelphia.  ISBN:978-1-4377-2523-0.

14. Samaratunga H. Squamous cell carcinoma, verrucous of penis. High Yield Uropathology.  Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012.  Elsevier Philadelphia. ISBN:978-1-4377-2523-0.

13. Samaratunga H. Urothelial carcinoma, micropapillary variant. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012.  Elsevier Philadelphia.  ISBN:978-1-4377-2523-0.

12. Samaratunga H. Chemotherapy-induced cystitis. High Yield Uropathology.  Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012. Elsevier Philadelphia. ISBN:978-1-4377-2523-0.

11. Samaratunga H. Cryptorchidism. High Yield Uropathology. Editors:  Zhou M, Netto G, and Epstein JI. 1stEdition 2012. Elsevier Philadelphia ISBN:978-1-4377-2523-0.

10. Samaratunga H. Juvenile granulosa cell tumour. Editors: Zhou M, Netto G, and Epstein JI. Editors. 1st Edition2012. Elsevier Philadelphia ISBN:978-1-4377-2523-0.

9. Samaratunga H. Aggressive angiomyxoma. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

8. Samaratunga H. Collecting duct carcinoma. High Yield Uropathology.  Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

7. Samaratunga H. Congenital mesoblastic nephroma. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

6. Samaratunga H. Post-atrophy hyperplasia. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

5. Samaratunga H. Prostatic carcinoma- foamy gland variant. High Yield UropathologyEditors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012.  Elsevier Philadelphia ISBN:978-1-4377-2523-0.

4. Samaratunga H. Ductal adenocarcinoma. High Yield Uropathology. Editors:  Zhou M, Netto G, and Epstein JI.1st Edition 2012. Elsevier Philadelphia ISBN:978-1-4377-2523-0.

3. Epstein JI, Algaba F, Allsbrook Jr WC, Bastacky S, Boccon-Gibod L, DeMarzo AM, Egevad L, Furusato M, Hamper UM, Helpap B, Humphrey PA, Icskowski KA, Lopez-Beltran A, Montironi R, Rubin MA, Sakr WA, Samaratunga H & Parkin DM.  Acinar adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 3rd edition. 2004. IARC Press.  Lyon. ISBN 92-832-21424.

2. Yang XJ, Cheng L, Helpap B & Samaratunga H.  Ductal adenocarcinomaTumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 3rd edition. 2004. IARC Press.  Lyon. ISBN 92-832-21424,

1. Iczkowski KA, Samaratunga HM, Cheng L, Helpap B, Parkinson MC, Yang XJ & Sesterhenn I. Tumours of the seminal vesicles. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 3rd edition. 2004. IARC Press.  Lyon.ISBN 92-832-21424